Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.03 +0.30 (+0.84%)
Official Closing Price Updated: 7:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,969,311
Open 35.99
Bid (Size) 35.03 (1)
Ask (Size) 36.26 (1)
Prev. Close 35.73
Today's Range 35.26 - 36.15
52wk Range 34.50 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Do I Need to Get A Polio Vaccine? New York Sewer Discovery Triggers Fears About Paralysis-Inducing Virus
New York officials have detected polio in the city's wastewater, suggesting the virus has been circulating in the local area. 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire

Performance

YTD
-17.49%
-17.49%
1 Month
-12.65%
-12.65%
3 Month
-18.80%
-18.80%
6 Month
-15.96%
-15.96%
1 Year
-14.38%
-14.38%

More News

Read More
Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
GSK Confirms Rotavirus Vaccine Shortage, Hits Four African Countries: Report
Via Benzinga
Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment
Via Benzinga
GSK, PFE, SNY Stocks Fall on Zantac Litigation
Via InvestorPlace
Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms
Via Investor's Business Daily
Sonos, Bumble And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
Via Benzinga
Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell
Via Investor's Business Daily
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Via Benzinga
Dividend Income Update July 2022
Via Talk Markets
ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
From GSK plc
Via Business Wire
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
Via Investor's Business Daily
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
From GSK plc
Via Business Wire
IDEAYA's Cancer Candidate Shows Early Tumor Modulation
Via Benzinga
The 3 Best Market Sectors for the Second Half of 2022
Via InvestorPlace
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback